The Rel/NF-kB family of transcription factors has been implicated in such diverse cellular processes as proliferation, differentiation, and apoptosis. As each of these processes occurs during post-natal mammary gland morphogenesis, the expression and activity of NF-kB factors in the murine mammary gland were examined. Immunohistochemical and immunoblot analyses revealed expression of the p105/p50 and RelA subunits of NF-kB, as well as the major inhibitor, IkBa, in the mammary epithelium during pregnancy, lactation, and involution. Electrophoretic mobility shift assay (EMSA) demonstrated that DNA-binding complexes containing p50 and RelA were abundant during pregnancy and involution, but not during lactation. Activity of an NF-kB-dependent luciferase reporter in transgenic mice was highest during pregnancy, decreased to near undetectable levels during lactation, and was elevated during involution. This highly regulated pattern of activity was consistent with the modulated expression of p105/p50, RelA, and IkBa. q
Results and discussion
The Rel/NF-kB family of ubiquitous, inducible transcription factors consists of multiprotein complexes specialized for rapid cellular responses to a wide variety of growth factor, cytokine, and pathogenic stimuli (Verma et al., 1995) . Although NF-kB activity has been well characterized in lymphoid tissues as a mediator of in¯ammatory and immune responses, several cell culture and in vivo models have implicated NF-kB in fundamental cellular processes, including proliferation and apoptosis (Verma et al., 1995; Attar et al., 1997; Ghosh et al., 1998) . Each of these processes are critical during the highly dynamic morphogenesis of the mammary gland (Medina, 1996) . Moreover, several recent studies have demonstrated aberrant expression of NF-kB factors and enhanced DNA binding activity in breast cancer cell lines and primary tumors (Dejardin et al., 1995; Nakshatri et al., 1997; Sovak et al., 1997 Sovak et al., , 1999 Cogswell et al., 2000) . Given these observations, the expression of several NF-kB/IkB family members over the course of post-natal mammary gland development was investigated. These family members included p105/p50, which acts as an NF-kB inhibitor in the 105 kDa isoform and as a transcriptional cofactor in the 50 kDa isoform, RelA, one of the major transcriptional activators in the NF-kB family, and IkBa, a direct inhibitor of NF-kB. In addition, the DNA-binding activity and in vivo transcription mediated by NF-kB throughout post-natal development was assessed.
Immunohistochemistry revealed expression of the p105/ p50 and RelA subunits of NF-kB and the direct inhibitor, IkBa, in the epithelium of virgin, pregnant, lactating, and involuting mammary glands (Fig. 1) . Expression was observed in both the epithelium and in the surrounding stroma, with a more intense and dynamic pattern within the epithelium. At 16.5 days of pregnancy, when the mammary epithelium is proliferating and beginning to www.elsevier.com/locate/modo express milk proteins, RelA expression appeared to be upregulated as compared to levels in the virgin epithelium (Fig.  1B) . IkBa expression appeared to be decreased at 3 days of involution, when the mammary epithelium is regressing by apoptosis, compared to 5.5 day fully differentiated, lactating epithelium (Fig. 1C) . Speci®city of the anti-p105/p50 antibody was con®rmed by probing sections from p105/p50-de®cient virgin mammary glands. The ductal morphology and histology of p105/p50-de®cient mammary glands appeared relatively normal, though a slight increase in lateral branching was observed in some samples (data not shown). Expression of p105/p50 was detected in wild-type virgin glands, while no staining was detected in glands collected from p105/p50-de®cient virgin animals (Fig.  1D) . Speci®city of anti-p105/p50 antisera, as well as antisera against RelA and IkBa, was also con®rmed by peptide competition. The colorimetric signal in sections probed with antisera minus speci®c competitor was more intense than in control sections probed with primary antisera that was presorbed with speci®c competitor peptides, but not in sections probed with primary antisera that was presorbed with non-speci®c peptides (Fig. 2) . Higher magni®cation of p105/p50 and RelA stained sections revealed both nuclear and cytoplasmic localization of these subunits in epithelium during pregnancy and involution (Fig. 3A) .
In order to quantify p105/p50, RelA, and IkBa expres- Fig. 1 . NF-kB and IkBa are expressed in the mammary gland epithelium over the course of post-natal morphogenesis. Histological sections were prepared from virgin, 16.5 day pregnant (16.5 dpc), 5.5 day lactating (5.5 lac), and 3 days post-wean involuting (3 dpw) number 3 thoracic glands. These sections were probed with primary antisera for p105/p50 (A), RelA (B), or IkBa (C). Epithelial expression of RelA increased at 16.5 days of pregnancy (B), whereas expression of IkBa decreased at 3 days post-wean involution. Histological sections from wild-type and p105/p50-de®cient mammary glands were probed with antisera against p105/p50 to con®rm the speci®city of the antisera. Expression of p105/p50 was detected in sections from wild-type virgin animals but not in sections from p105/p50-de®cient virgin animals (D). Data presented are a representation of results from three to six independent samples per developmental stage. Scale bar, 50 mm. Histological sections were prepared from number 3 thoracic glands collected from 3 days post-wean involuting (3 dpw) mice as both NF-kB factors and IkBa are expressed at detectable levels during this stage of development. These sections were probed with primary antisera for p105/ p50 (A), RelA (B), or IkBa (C), with or without 5-fold excess of speci®c competitor peptides or non-speci®c peptides against p52. The speci®c peptides abrogated the signal (left hand panel versus middle), whereas the non-speci®c peptides did not (left hand panel versus right), demonstrating the speci®city of these antisera for NF-kB factors and IkBa. Data presented are a representation of results from three independent samples per condition. Scale bar, 50 mm.
sion over the course of post-natal mammary gland morphogenesis, immunoblot analysis was performed on nuclear and cytoplasmic protein extracts from virgin, pregnant, lactating, and involuting mammary glands (Fig. 3B ). Enrichment of cytoplasmic and nuclear proteins within these extracts was con®rmed by using antibodies directed against b-tubulin, a cytoplasmic protein, and SP1, a nuclear factor (Fig.  3B ). SP1 expression in nuclear extracts from involuting mammary samples was not observed, however, likely due to the cessation of much general transcription due to massive epithelial apoptosis during these stages. The presence of intact proteins in these extracts and the relative uniformity of loading was con®rmed by Ponceau S stain following transfer of SDS-PAGE fractionated proteins to polyvinylidine¯uoride (PVDF) membranes (data not shown). IkBa functions as an inhibitor of NF-kB nuclear import primarily in the cytoplasm, and uniform IkBa expression was observed in cytoplasmic extracts from virgin, pregnant, and early lactating glands. Cytoplasmic expression of IkBa was observed to decrease in late lactation and involution. Cytoplasmic levels of latent p50 and RelA were also relatively uniform. Upon activation, NF-kB complexes are known to be transported to the nucleus, and an increase in nuclear RelA expression was observed in pregnancy as compared to virgin samples, and again at 1 and 3 days involution as compared to 9.5 days lactation. Again, speci®city of the p105/p50 antibody was con®rmed by probing cytoplasmic extracts from wild-type virgin glands and from p105/p50-de®cient glands with anti-p105/ p50 antisera. Expression of p105/p50 was detected only in extracts from wild-type mammary glands, and uniform loading of proteins was con®rmed by probing with an antibody against b-tubulin (Fig. 3C ). These data demonstrate a dynamic pattern of expression and intracellular localization for p105/p50, RelA, and IkBa in the mammary gland epithelium. Electrophoretic mobility shift assays were performed on mammary gland nuclear extracts to assess the pattern of NFkB DNA-binding activity during pregnancy, lactation, and involution. An oligonucleotide bearing an NF-kB consensus element from the human immunode®ciency virus-long terminal repeat (HIV-LTR) was used to detect nuclear NF-kB in these extracts. This enhancer binds a broad range of NF-kB homodimeric and heterodimeric complexes (Kretzschmar et al., 1992; Liu et al., 1992; Doerre et al., 1993) . Two protein complexes capable of binding to this NF-kB consensus element were observed in mammary gland nuclear extracts. The relatively strong complex (Complex A) migrated with a higher mobility than the weaker complex (Complex B; Fig. 4A ). Speci®city of the protein:DNA complex was demonstrated by the addition of excess unlabeled competitor oligonucleotides to 16.5 day pregnant, 5.5 day lactation, and 3 day post-wean samples (Fig. 4A, lanes 3, 7, and 11 ). DNA binding activity was Fig. 3 . NF-kB factors are localized to both the nuclei and cytoplasm of mammary epithelium during pregnancy and involution. Higher magni®cation of 16.5 dpc and 3 dpw sections probed for p105/p50 and RelA expression revealed nuclear localization in several epithelial cells (A, arrowhead) in addition to the cytoplasmic localization in adjacent cells. Scale bar, 10 mm. Cytoplasmic and nuclear protein extracts (15 mg) from mammary glands or FL5.12 pro-B cells as a positive control were subjected to immunoblot analysis for expression of IkBa, p105/p50, and RelA (B) or for b-tubulin and SP1 as cytoplasmic and nuclear markers, respectively. IkBa expression in the cytoplasm was uniform until 9.5 days lactation (9.5 lac), when levels decreased continuing through 1, 3 and 5 days involution (1, 3, 5 dpw). Expression of p50 and RelA was relatively uniform in the cytoplasm. Nuclear RelA expression increased in pregnancy and involution. The speci®city of the p105/p50 antisera was con®rmed by immunoblot analysis probing cytoplasmic extracts (30 mg) from wild-type or p105/p50-de®cient virgin mammary glands (C). Expression of p105/p50 was detected in cytoplasmic extracts prepared from wild-type mammary glands, but not in extracts prepared from p105/p50-de®cient glands. Antisera against b-tubulin was used to con®rm that equal quantities of protein were loaded for each sample (C). Data presented are a representation of results from three to six independent samples per developmental stage.
highest during pregnancy, decreased substantially through lactation, and then increased following cessation of nursing, as recently described by others (Clarkson and Watson, 1999) . To provide a more detailed characterization of these DNA-binding complexes, antibodies recognizing speci®c family members were used for supershifts to iden- Fig. 5 . In vivo transcriptional activity of NF-kB in the mammary glands of transgenic reporter mice is highest during pregnancy and involution. Protein extracts were prepared from virgin, pregnant (10.5, 12.5, 14.5, 16.5, and 18.5 dpc), lactating (1.5, 3.5, 5.5, 7.5, and 9.5 lac), and involuting (1, 3, and 5 dpw) number 4 inguinal mammary glands from transgenic mice expressing luciferase under the regulation of the HIV-LTR or from non-transgenic animals at 10.5 days of pregnancy. Luciferase activity (relative light units, RLUs) was assessed in 20 ml of protein extract. Data were normalized based on protein concentration and are the average of three independent samples per developmental stage with standard error of the mean. Fig. 4 . DNA binding activity of NF-kB in mammary gland nuclear extracts is highest during pregnancy and involution. Nuclear extracts were prepared from virgin, pregnant (10.5 and 16.5 dpc), lactating (5.5 and 9.5 lac), and involuting (1, 3, and 5 dpw) number 4 inguinal glands. Nuclear extracts (10 mg) were incubated with an end-labeled oligonucleotide harboring an NF-kB enhancer element from the HIV-LTR. Two protein complexes capable of binding this oligonucleotide were present in virgin, pregnant, and involuting mammary samples, a strong complex (Complex A) migrating below a relatively weaker complex (Complex B; A). The speci®city of these complexes was con®rmed by competition with excess, unlabeled oligonucleotide (A; lanes 3, 7, and 11). Supershifts for p50 and RelA con®rmed the presence of these NF-kB components in the complex (A; lanes 5, 6, 13, and 14). In order to con®rm the speci®city of the antisera used to supershift p50, nuclear extracts prepared from virgin p105/p50-de®cient mice were probed with anti-p50 antisera. DNA-binding in p105/ p50-de®cient nuclear extracts (10 mg) was apparent, although reduced compared to that in wild-type nuclear extracts (B; lane 1 versus lane 5). The antisera used to detect p50 in EMSA experiments was speci®c, as a supershift was detected in wild-type but not p105/p50-de®cient nuclear extracts (B; lane 3 versus lane 7). Data presented are a representation of three to six independent samples per developmental stage.
tify speci®c NF-kB family members. In nuclear extracts prepared from mammary glands at 16.5 dpc, a supershift was produced by an antibody against p50 (Fig. 4A, lane  5) . RelA is was also supershifted in nuclear extracts prepared from mammary glands at 16.5 dpc (Fig. 4A, lane  6 ). RelA and p50 supershifts were also detected in nuclear extracts prepared from mammary glands at 3 dpw (Fig. 4A,  lanes 13 and 14) . The speci®city of the p105/p50 antibody used in supershift experiments was con®rmed by incubating the antibody with nuclear extracts from virgin p105/p50-de®cient mammary glands. Nuclear extracts from p105/ p50-de®cient mice exhibited a decrease in the level of DNA-binding relative to extracts from wild-type mammary glands, although DNA-binding was still present (Fig. 4B,  lane 1 versus lane 5) . No p50 supershift was observed in nuclear extracts prepared from virgin p105/p50-de®cient mammary glands, although the anti-p50 antisera was able to produce a supershift in nuclear extracts prepared from wild-type virgin mammary glands (Fig. 4B , lane 3 versus lane 7). No supershift was detected with the RelA antisera in p105/p50-de®cient glands, though the more slowly migrating DNA-binding complex in p105/p50-de®cient extracts appears to co-migrate with the more slowly migrating DNA-binding complex in wild-type virgins (Fig. 4B , lane 4 versus lane 8). It is possible that this complex contains RelA but that the levels are below the detection limits in this assay (Fig. 4B, lane 8 ). These data demonstrate the dynamic DNA-binding activity of nuclear p50 and RelA containing complexes in the mammary gland during post-natal morphogenesis.
In order to assess the transactivational function of NF-kB in vivo, the activity of an NF-kB responsive reporter was monitored in the mammary glands of transgenic mice at various developmental stages. Transgenic mice bearing the human immunode®ciency virus long terminal repeat (HIV-LTR) driving the Photinus luciferase cDNA, termed HLLs, have been used to quantify both constitutive and induced NF-kB activity (Blackwell et al., 2000) . Moderate reporter activity was detected in virgin glands, compared to background levels in non-transgenic control glands (Fig. 5) . Luciferase activity increased consistently through midpregnancy (10.5±16.5 dpc), and then decreased in late pregnancy (18.5 dpc, Fig. 5 ). NF-kB activity levels decreased dramatically between 3.5 and 5.5 days of lactation, matching the levels measured in non-transgenic control glands. When pups were removed after 9.5 days of lactation, to induce epithelial involution, an increase in NF-kB reporter activity was observed.
Immunohistochemistry and immunoblot analyses revealed speci®c expression of p105/p50, RelA, and IkBa members in the developing mammary epithelium. Nuclear p50 and RelA expression was upregulated during pregnancy and involution. In addition, EMSA and the activity of an NF-kB inducible reporter in transgenic mice revealed elevated NF-kB activity during pregnancy and involution post-weaning. DNA-binding and transcriptional activity were dramatically reduced during lactation. These highly regulated and dynamic expression and activity patterns indicate that further studies are imperative to determine the speci®c functions of NF-kB in mammary epithelial development during pregnancy and involution.
Materials and methods

Immunohistochemistry
Paraformaldehyde-®xed, paraf®n-embedded sections (5± 7 mm) from number 3 thoracic glands of virgin, 16.5 day pregnant, 5.5 day lactating, and 3 day involuting (after forced wean at 9.5 days lactation) B6D2 mice were probed with primary antisera (rabbit anti-IkBa, SC-371, 1 mg/ml; rabbit anti-p105/p50, SC-114, 2 mg/ml; rabbit anti-RelA, SC-109, 5 mg/ml; Santa Cruz Biotechnology). For peptide competition assays, primary antisera were incubated with a 5-fold excess of speci®c peptides as per supplied protocol (Santa Cruz) prior to immunohistochemistry, or with a 5-fold excess of non-speci®c peptides directed against p52 (SC-298P, Santa Cruz) as a negative control. Speci®c immunoreaction was detected using the Vectastain Elite ABC kit (Vector Laboratories) and 3,3
H -Diaminobenzidine tetrahydrochloride (DAB) horseradish peroxidase substrate (Zymed Laboratories) according to manufacturer's protocols. Sections were counterstained with hematoxylin prior to dehydration, mounting, and photodocumentation.
Immunoblot
Nuclear and cytoplasmic extracts were prepared using number 4 inguinal mammary glands collected from virgin, 10.5 and 16.5 day pregnant, 5.5 and 9.5 day lactating, and 1, 3 and 5 day post forced wean animals as described by Baldwin et al. (1991) . Whole cell extracts from the FL5.12 pro-B cell line were used as a positive control for NF-kB/IkB expression, as progenitor B-cells are known to express these factors (Grumont and Gerondakis, 1994) . Protein concentration was determined using a Lowry assay (BioRad Protein Assay Kit). Protein extracts (15 or 30 mg) were fractionated on 8±12% SDS-polyacrylamide gels and transferred to polyvinylidine¯uoride (PVDF) membranes (Immobilon). The membranes were probed with primary antisera (rabbit anti-IkBa SC-371, 1 mg/ml; rabbit antip105/p50, NR1157, 1:1000, generously provided by Dr Nancy Rice, National Cancer Institute; rabbit anti-RelA, SC-109, 2 mg/ml; rabbit anti-SP1, SC-59, 1 mg/ml; mouse anti-b-tubulin, N-357, 1:1000, Amersham) according to manufacturer's protocol (Santa Cruz Biotechnology). The speci®city of the NR1157 antisera for immunoblot was con®rmed previously by comparing expression in wildtype murine thymic cell extracts versus extracts from p105/p50 de®cient mice (Pereira et al., 1996) . The membranes were then incubated with a horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse secondary antisera (Southern Biotechnology Associates)
